



**For Immediate Release
June 30, 2016**

SUNSHINE BIOPHARMA SIGNS LICENSING AGREEMENT FOR THREE ADDITIONAL GENERIC PRODUCTS FOR TREATMENT OF CANCER AND BPH

Montreal, QC – (Marketwired – June 30, 2016) – Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, is pleased to announce that it has signed a Cross Referencing Agreement with a major pharmaceutical company for three additional prescription generic drugs for treatment of Breast Cancer, Prostate Cancer and Enlarged Prostate. Sunshine will market and sell these new pharmaceutical products under its own label.

Sunshine's three new generic products together with the previously announced initial generic product are as follows:

- Anastrozole (brand name Arimidex® by AstraZenica) for treatment of Breast Cancer
- Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer
- Bicalutamide (brand name Casodex® by AstraZenica) for treatment of Prostate Cancer
- Finasteride (brand name Propecia® by Merck) for treatment of BPH (Benign Prostatic Hyperplasia)

Worldwide sales of the brand name version of these products as reported by the respective owner of the registered trademark are as follows:

- Arimidex® \$250M in 2015
- Femara® \$380M in 2014
- Casodex® \$267M in 2015
- Propecia® \$183M in 2015

Sunshine is currently in the process of securing a Drug Identification Number ("DIN") for each of these products from Health Canada. The Company is also working on obtaining a Drug Establishment License ("DEL") from Health Canada. Upon receipt of the DEL and DIN's, Sunshine will be able to accept orders for its own label SBI-Anastrozole, SBI-Letrozole, SBI-Bicalutamide and SBI-Finasteride. Sunshine expects to build a portfolio of "SBI" label Generic Pharmaceuticals over time.

Revenues from sales of Generic Products are intended to be used to finance the Company's proprietary drug development program including Adva-27a, the Company's flagship anticancer compound. A Topoisomerase II inhibitor, Adva-27a is a small molecule that has recently been shown to be effective at destroying Multidrug Resistant Breast Cancer cells, Pancreatic Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Number 8,236,935.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:

Sunshine Biopharma Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com